P3–270: A 24‐week, open‐label extension to the ACTivities of daily living and cognitION (ACTION) study: Long‐term safety, tolerability and efficacy of a 13.3 mg/24 h rivastigmine patch in people with severe Alzheimer's disease. (1st July 2013)